BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20958960)

  • 1. Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer.
    Shibata MA; Morimoto J; Shibata E; Kurose H; Akamatsu K; Li ZL; Kusakabe M; Ohmichi M; Otsuki Y
    BMC Cancer; 2010 Oct; 10():566. PubMed ID: 20958960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation.
    Shibata MA; Iinuma M; Morimoto J; Kurose H; Akamatsu K; Okuno Y; Akao Y; Otsuki Y
    BMC Med; 2011 Jun; 9():69. PubMed ID: 21639868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.
    Morishima S; Shibata MA; Ohmichi M; Otsuki Y
    Med Mol Morphol; 2008 Sep; 41(3):132-8. PubMed ID: 18807138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
    Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
    J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
    Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
    Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective action of raloxifene against hypoxia-induced damage in mouse hippocampal cells depends on ERα but not ERβ or GPR30 signalling.
    Rzemieniec J; Litwa E; Wnuk A; Lason W; Gołas A; Krzeptowski W; Kajta M
    J Steroid Biochem Mol Biol; 2015 Feb; 146():26-37. PubMed ID: 24846829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
    Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
    Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
    Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
    Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
    J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.
    Balaburski GM; Dardes RC; Johnson M; Haddad B; Zhu F; Ross EA; Sengupta S; Klein-Szanto A; Liu H; Lee ES; Kim H; Jordan VC
    Int J Oncol; 2010 Aug; 37(2):387-98. PubMed ID: 20596666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation.
    Shibata MA; Akao Y; Shibata E; Nozawa Y; Ito T; Mishima S; Morimoto J; Otsuki Y
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):681-91. PubMed ID: 17256131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells.
    Takahashi K; Ohmichi M; Yoshida M; Hisamoto K; Mabuchi S; Arimoto-Ishida E; Mori A; Tsutsumi S; Tasaka K; Murata Y; Kurachi H
    J Endocrinol; 2003 Aug; 178(2):319-29. PubMed ID: 12904179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
    Lamb CA; Helguero LA; Fabris V; Lucas C; Molinolo AA; Lanari C
    Breast Cancer Res Treat; 2003 May; 79(1):25-35. PubMed ID: 12779079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model.
    Shibata MA; Ambati J; Shibata E; Albuquerque RJ; Morimoto J; Ito Y; Otsuki Y
    BMC Med; 2010 Nov; 8():69. PubMed ID: 21047425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells.
    Janakiram NB; Mohammed A; Brewer M; Bryant T; Biddick L; Lightfoot S; Pathuri G; Gali H; Rao CV
    Cancer Prev Res (Phila); 2014 Mar; 7(3):300-9. PubMed ID: 24431404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).
    Ning M; Zhou C; Weng J; Zhang S; Chen D; Yang C; Wang H; Ren J; Zhou L; Jin C; Wang MW
    Br J Pharmacol; 2007 Jan; 150(1):19-28. PubMed ID: 17115070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
    Hoffman KL; Lerner SP; Smith CL
    Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.